Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock Holdings Lifted by Schroder Investment Management Group

Schroder Investment Management Group grew its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 63.3% in the 4th quarter, Holdings Channel reports. The institutional investor owned 147,002 shares of the company’s stock after acquiring an additional 56,961 shares during the period. Schroder Investment Management Group’s holdings in Dyne Therapeutics were worth $3,477,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in DYN. Bank of New York Mellon Corp lifted its stake in Dyne Therapeutics by 0.3% in the fourth quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company’s stock valued at $5,532,000 after acquiring an additional 698 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Dyne Therapeutics during the 3rd quarter valued at $34,000. KBC Group NV lifted its stake in shares of Dyne Therapeutics by 45.3% in the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock valued at $74,000 after purchasing an additional 978 shares during the last quarter. Virtue Capital Management LLC boosted its holdings in Dyne Therapeutics by 4.4% in the third quarter. Virtue Capital Management LLC now owns 23,208 shares of the company’s stock worth $834,000 after purchasing an additional 981 shares in the last quarter. Finally, Point72 DIFC Ltd acquired a new position in Dyne Therapeutics during the third quarter worth $36,000. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Stock Performance

NASDAQ DYN opened at $8.28 on Friday. Dyne Therapeutics, Inc. has a twelve month low of $8.15 and a twelve month high of $47.45. The stock has a market cap of $936.64 million, a PE ratio of -2.33 and a beta of 1.21. The firm has a 50-day simple moving average of $12.81 and a 200 day simple moving average of $22.61.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. Research analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the transaction, the insider now directly owns 199,087 shares in the company, valued at $2,777,263.65. This represents a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 6,237 shares of company stock valued at $77,760 over the last quarter. Corporate insiders own 20.77% of the company’s stock.

Analyst Ratings Changes

DYN has been the subject of a number of analyst reports. Scotiabank started coverage on Dyne Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 price target for the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $45.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. HC Wainwright reiterated a “buy” rating and set a $46.00 price target on shares of Dyne Therapeutics in a report on Monday, March 17th. Baird R W upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. Finally, Robert W. Baird started coverage on shares of Dyne Therapeutics in a research note on Friday, December 13th. They issued an “outperform” rating and a $46.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $47.46.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.